4 months ago
2
Granules India posted 28% higher nett net for the 3rd 4th ended December astatine ₹150.2 crore compared with ₹117.6 crore a twelvemonth earlier.
Revenue from operations stood astatine ₹1,387.9 crore (₹1,137.7 crore), an summation of 22%, which the generic drugmaker said was driven by the Finished Dosages (FD) conception successful North America and Europe. FD, progressive pharmaceutical ingredients (API), pharmaceutical formulation intermediates (PFI) and peptides/ CDMO contributed 76%, 11%, 11% and 2% of gross from operations respectively during the quarter, the institution said.
“Q3 has been 1 of our strongest quarters, reflecting disciplined execution of strategical maturation initiatives, and we are well-positioned for sustained maturation momentum,” CMD Krishna Prasad Chigurupati said.
Nod for money rise
The institution got support of the shareholders connected January 22 for its plans to rise ₹1,762.50 crore done contented of preferential convertible warrants and equity shares. The Board had successful December fixed approval for contented of 2.5 crore convertible warrants for ₹585 each aggregating up to ₹1,462.50 crore connected preferential ground to members of the promoter radical and non-promoter capitalist category; and done contented of a much than 51.28 lakh equity shares (face worth of ₹1 each) for ₹585 per share, aggregating up to ₹300 crore connected preferential ground to assorted non-promoter capitalist category.
